Tweets
AutifonyLtd @AutifonyLtd
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more.
Barbara's experience… https://t.co/u0VXnvXlGI
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
News & Events
Tweets
AutifonyLtd @AutifonyLtd
Autifony Therapeutics regains rights to clinical stage Kv3 programme
https://t.co/rBHjjR7aC0
RT @singular_talent:Barbara Domayne-Hayman joined us on Careers in Discovery to talk startups, careers and more.
Barbara's experience… https://t.co/u0VXnvXlGI
Autifony announces commencement of a Phase I study of AUT00201, a novel Kv3 modulator for schizophrenia and hearing… https://t.co/oeGgN4ooWG
Comments are closed.